Human Gene Therapy Methods · 2012 · 24 citations · 51 references
MedicineOncologyPharmacologyDrug DeliveryGene DeliveryGene TherapyGene Delivery VectorsGlioblastomaReactive GliosisAdenoviral TransgenesisAdenoviral VectorsAdenovirus VectorsBiodistribution StudiesGene-targeted TherapyTherapeutic ImmunostimulationTransgene ExpressionViral Vector Delivery
Adenoviral vectors (Ads) have been evaluated in clinical trials for glioma. However, systemic immunity against the vectors can hamper therapeutic efficacy. We demonstrated that combined immunostimulation and cytotoxic gene therapy provides long-term survival in preclinical glioma models. Because helper-dependent high-capacity Ads (HC-Ads) elicit sustained transgene expression, in the presence of antiadenoviral immunity, we engineered HC-Ads encoding conditional cytotoxic herpes simplex type 1 thymidine kinase and immunostimulatory cytokine Fms-like tyrosine kinase ligand-3 under the control of the TetOn system. Escalating doses of combined HC-Ads (1×108, 1×109, and 1×1010 viral particles [VP]) were delivered into the rat brain. We assessed neuropathology, biodistribution, transgene expression, systemic toxicity, and behavioral impact at acute and chronic time points after vector delivery. Histopathological analysis did not reveal any evidence of toxicity or long-term inflammation at the lower doses tested. Vector genomes were restricted to the injection site. Serum chemistry did not uncover adverse systemic side effects at any of the doses tested. Taken together, our data indicate that doses of up to 1×109 VP of each HC-Ad can be safely administered into the normal brain. This comprehensive toxicity and biodistribution study will lay the foundations for implementation of a phase 1 clinical trial for GBM using HC-Ads. Muhammad and colleagues engineer High-Capacity Adenoviral vectors (HC-Ads) encoding conditional cytotoxic herpes simplex type 1 thymidine kinase and immunostimulatory cytokine fms-like tyrosine kinase ligand 3 under the control of the Tetracycline On system and administer escalating doses of combined vector into the rat brain. Comprehensive toxicity and biodistribution studies showed that doses up to 1×109 vp per HC-Ad were safely tolerated in normal brains. Instructions for Authors can be found on our website atwww.liebertpub.com/hgtb
51
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Immune responses to adenovirus and adeno-associated virus in humans
Narendra Chirmule, Kathleen J. Propert, Susan Magosin et al. · Gene Therapy · 1999 · 681 citations
The brain tumor microenvironment
Nikki Charles, Eric C. Holland, Richard J. Gilbertson et al. · Glia · 2011 · 678 citations
Medicine, Neuroscience, Oncology +17